2022/04/11 更新

写真a

コンドウ　チアキ
近藤　千晶
KONDO Chiaki
所属
医学部附属病院 ゲノム医療センター 病院助教
職名
病院助教

学位 1

  1. 博士（医学） （ 2019年10月   名古屋大学 ） 

学位の先頭へ▲
 

論文 9

  1. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL     2021年10月

    　詳細を見る

    記述言語：日本語  

    DOI： 10.1007/s13691-021-00517-8

    Web of Science

  2. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL     2021年10月

    　詳細を見る

    記述言語：日本語  

    DOI： 10.1007/s13691-021-00515-w

    Web of Science

  3. [Superior Vena Cava Syndrome].

    Kondo C, Asai G

    Gan to kagaku ryoho. Cancer & chemotherapy   47 巻 ( 6 ) 頁： 870 - 874   2020年6月

    　詳細を見る

    記述言語：日本語  

    PubMed

  4. Anaplastic lymphoma kinase expression in small‐cell lung cancer

    Chiaki Kondoh, Yoshitsugu Horio, Yuko Hayashi, Hiromichi Ebi, Toyoaki Hida, Yoshinori Hasegawa, Yasushi Yatabe

    Histopathology   75 巻 ( 1 ) 頁： 20 - 28   2019年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：Wiley  

    Aims: Anaplastic lymphoma kinase (ALK) immunohistochemistry has shifted from being a screening tool to being a sole determinant for ALK-targeted therapy. Recent articles have referred to small-cell lung cancer (SCLC) transformation as a resistance mechanism after ALK inhibitor treatments, but few reports have addressed ALK expression in treatment-naive SCLC in a comprehensive manner. Therefore, we examined ALK expression and the mechanisms in treatment-naive SCLCs. Methods and results: We examined ALK expression in a consecutive series of SCLC tumours, and the expression mechanism was analysed regarding gene rearrangement, copy number changes, and point mutations. We also examined whether SCLC with ALK expression can be suppressed by crizotinib treatment in vitro. Immunohistochemical results revealed that ALK was expressed in 16 of 142 (11.3%) SCLCs. The expression was focal and less intense, which is in contrast to strong and uniform expression in adenocarcinoma with ALK rearrangement. Two combined SCLCs showed a positive reaction restricted to the SCLC component. None of the known genetic alterations, including rearrangement, amplification, copy number gain, or point mutations, were associated with ALK expression. A SCLC cell line, SKLC2, which expressed ALK without known genetic alterations, was not inhibited by a practically achievable serum concentration of crizotinib. Conclusions: Anaplastic lymphoma kinase immunohistochemistry for treatment-naive SCLCs should not be used as a predictive biomarker for ALK inhibitor therapy, because the positive reactions were due to intrinsic expression of normal ALK transcript.

    DOI： 10.1111/his.13842

    Web of Science

    Scopus

    PubMed

    CiNii Research

  5. Pathologic Diagnosis and Genetic Analysis of a Lung Tumor Needle Biopsy Specimen Obtained Immediately After Radiofrequency Ablation.

    Hasegawa T, Kondo C, Sato Y, Inaba Y, Yamaura H, Kato M, Murata S, Onoda Y, Kuroda H, Sakao Y, Yatabe Y

    Cardiovascular and interventional radiology   41 巻 ( 4 ) 頁： 594 - 602   2018年4月

    　詳細を見る

    記述言語：英語  

    DOI： 10.1007/s00270-017-1845-4

    PubMed

  6. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.

    Oya Y, Yoshida T, Kuroda H, Mikubo M, Kondo C, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y

    Oncotarget   8 巻 ( 61 ) 頁： 103117 - 103128   2017年11月

    　詳細を見る

    記述言語：英語  

    DOI： 10.18632/oncotarget.21602

    PubMed

  7. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

    Kobayashi Y., Togashi Y., Yatabe Y., Mizuuchi H., Jangchul P., Kondo C., Shimoji M., Sato K., Suda K., Tomizawa K., Takemoto T., Hida T., Nishio K., Mitsudomi T.

    Clinical Cancer Research   21 巻 ( 23 ) 頁： 5305 - 5313   2015年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：Clinical Cancer Research  

    Purpose: Lung cancers harboring common EGFR mutations respond to EGFR tyrosine kinase inhibitors (TKI), whereas exon 20 insertions (Ins20) are resistant to them. However, little is known about mutations in exon 18. Experimental Design: Mutational status of lung cancers between 2001 and 2015 was reviewed. Three representative mutations in exon 18, G719A, E709K, and exon 18 deletion (Del18: delE709-T710insD) were retrovirally introduced into Ba/F3 and NIH/3T3 cells. The 90% inhibitory concentrations (IC90s) of first-generation (1G; gefitinib and erlotinib), secondgeneration (2G; afatinib, dacomitinib, and neratinib), and third-generation TKIs (3G; AZD9291 and CO1686) were determined. Results: Among 1,402 EGFR mutations, Del19, L858R, and Ins20 were detected in 40%, 47%, and 4%, respectively. Exon 18 mutations, including G719X, E709X, and Del18, were present in 3.2%. Transfected Ba/F3 cells grew in the absence of IL3, and NIH/3T3 cells formed foci with marked pile-up, indicating their oncogenic abilities. IC90s of 1G and 3G TKIs in G719A, E709K, and Del18 were much higher than those in Del19 (by >1150- fold), whereas IC90s of afatinib were only 3- to 7-fold greater than those for Del19. Notably, cells transfected with G719A and E709K exhibited higher sensitivity to neratinib (by 525-fold) than those expressing Del19. Patients with lung cancers harboring G719X exhibited higher response rate to afatinib or neratinib (80%) than to 1G TKIs (35%56%) by compilation of data in the literature. Conclusions: Lung cancers harboring exon 18 mutations should not be overlooked in clinical practice. These cases can be best treated with afatinib or neratinib, although the currently available in vitro diagnostic kits cannot detect all exon 18 mutations.

    DOI： 10.1158/1078-0432.CCR-15-1046

    Scopus

    PubMed

  8. [Lung cancer: progress in diagnosis and treatments. Topics: II. Diagnosis and examination; 3. Pathological diagnosis, molecular testing and biomarkers].

    Kondo C, Yatabe Y

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine   103 巻 ( 6 ) 頁： 1281 - 6   2014年6月

    　詳細を見る

    記述言語：日本語  

    DOI： 10.2169/naika.103.1281

    PubMed

  9. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy.

    Park J, Yamaura H, Yatabe Y, Hosoda W, Kondo C, Shimizu J, Horio Y, Yoshida K, Tanaka K, Oguri T, Kobayashi Y, Hida T

    Cancer medicine   3 巻 ( 1 ) 頁： 118 - 23   2014年2月

    　詳細を見る

    記述言語：英語  

    DOI： 10.1002/cam4.172

    PubMed

▼全件表示

論文の先頭へ▲